These remarks stem from the findings of the ORAL Surveillance trial, which raised concerns about the cardiovascular (CV) safety of tofacitinib compared to that of tumor necrosis factor inhibitors (TNFis) in RA patients aged 50 years or older with at least one additional CV risk factor (Ytterberg et al., 2022). This evidence concerns the gene TNF and rheumatoid arthritis.